A PET STUDY OF DOPAMINERGIC ACTIVITY WITH ARMODAFINIL
阿莫达非尼多巴胺能活性的宠物研究
基本信息
- 批准号:8357964
- 负责人:
- 金额:$ 1.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-05-01 至 2012-04-30
- 项目状态:已结题
- 来源:
- 关键词:AffinityAltropaneAttention deficit hyperactivity disorderBrainCatecholaminesCorpus striatum structureDiseaseDopamineDopamine AgonistsDoseEnrollmentEvaluationFundingGrantHumanIsomerismLifeModafinilNarcolepsyNational Center for Research ResourcesNew EnglandNorepinephrinePharmaceutical PreparationsPlasmaPositron-Emission TomographyPrimatesPrincipal InvestigatorRacloprideReportingResearchResearch InfrastructureResourcesSiteSourceTherapeuticUnited States National Institutes of Healthbaseclinically relevantcostextracellularhuman subjectin vivoinhibitor/antagonistneuropsychiatrynonhuman primate
项目摘要
This subproject is one of many research subprojects utilizing the resources
provided by a Center grant funded by NIH/NCRR. Primary support for the subproject
and the subproject's principal investigator may have been provided by other sources,
including other NIH sources. The Total Cost listed for the subproject likely
represents the estimated amount of Center infrastructure utilized by the subproject,
not direct funding provided by the NCRR grant to the subproject or subproject staff.
AIMS: The stimulant modafinil and its active isomer r-modafinil (armodafinil) are approved for the treatment of narcolepsy and undergoing assessment to treat other neuropsychiatric disorders. Armodafinil is more potent, has a longer duration of action, and contains no inactive components. Both were designated atypical because of their unknown mechanism of action. In a PET imaging study in nonhuman primates, we reported that clinically relevant doses of modafinil occupied the dopamine (DAT) and norepinephrine (NET) transporters in living brain, conceivably elevating extracellular catecholamine levels in brain and nullifying its "atypical" designation. We now report whether these findings in primates extend to human brain with armodafinil. METHODS: Twelve human subjects were enrolled. Plasma armodafinil levels were obtained and in vivo armodafinil occupancy of the DAT in striatum was detected by (11C)altropane. Changes in extracellular dopamine were detected by indirect displacement of the D2 dopamine receptor agonist (11C)raclopride in human subjects. RESULTS: Armodafinil occupied striatal DAT (100 mg PO: 34 percent-40 percent, 1- 2.5 hrs, n=6; 250 mg: 60 percent-percent, 1-2.5 hrs; n=6). Armodafinil resulted in modest increases in extracellular dopamine levels, at both doses. CONCLUSIONS: Armodafinil cccupancy of the DAT and elevation of extracellular dopamine in vivo further implicate the DAT as a therapeutic site of action. These findings validate our previous discovery in nonhuman primates, support evaluation of armodafinil for dopamine-related disorders, e.g. attention deficit hyperactivity disorder, highlight the therapeutic potential of low affinity DAT inhibitors, and possibly the abuse liability of this previously designated class of "atypical" drugs.
这个子项目是许多利用资源的研究子项目之一
由NIH/NCRR资助的中心拨款提供。子项目的主要支持
而子项目的主要调查员可能是由其他来源提供的,
包括其它NIH来源。 列出的子项目总成本可能
代表子项目使用的中心基础设施的估计数量,
而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。
目标:兴奋剂莫达非尼及其活性异构体r-莫达非尼(阿莫达非尼)被批准用于治疗发作性睡病,并正在接受评估以治疗其他神经精神疾病。阿莫达非尼更有效,作用持续时间更长,不含非活性成分。由于其作用机制未知,两者均被指定为非典型。在非人灵长类动物的PET成像研究中,我们报告了临床相关剂量的莫达非尼占据了活体脑中的多巴胺(DAT)和去甲肾上腺素(NET)转运蛋白,可以想象地提高了脑中细胞外儿茶酚胺水平,并取消了其“非典型”名称。我们现在报告这些在灵长类动物中的发现是否会扩展到人类大脑。方法:招募了12名人类受试者。获得血浆阿莫达非尼水平,并通过(11 C)阿托烷检测纹状体中DAT的体内阿莫达非尼占有率。通过间接置换D2多巴胺受体激动剂(11 C)雷氯必利检测人类受试者细胞外多巴胺的变化。结果:阿莫达非尼占据纹状体DAT(100 mg PO:34%-40%,1- 2.5 h,n=6; 250 mg:60%,1-2.5 h; n=6)。在两种剂量下,阿莫达非尼均导致细胞外多巴胺水平适度增加。结论:阿莫达非尼对DAT的抑制和体内细胞外多巴胺的升高进一步暗示DAT是治疗作用部位。这些发现验证了我们先前在非人灵长类动物中的发现,支持对阿莫达非尼用于多巴胺相关疾病(例如注意缺陷多动障碍)的评价,突出了低亲和力DAT抑制剂的治疗潜力,以及这种先前指定的“非典型”药物类别的可能滥用倾向。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Bertha K Madras其他文献
Bertha K Madras的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Bertha K Madras', 18)}}的其他基金
Long Term THC Elicits Distinct Changes in Adolescent Brain Dopamine Signaling
长期使用 THC 会引起青少年大脑多巴胺信号的明显变化
- 批准号:
9979805 - 财政年份:2017
- 资助金额:
$ 1.38万 - 项目类别:
Long Term THC Elicits Distinct Changes in Adolescent Brain Dopamine Signaling
长期使用 THC 会引起青少年大脑多巴胺信号的明显变化
- 批准号:
9308499 - 财政年份:2017
- 资助金额:
$ 1.38万 - 项目类别:
Long Term THC Elicits Distinct Changes in Adolescent Brain Dopamine Signaling
长期使用 THC 会引起青少年大脑多巴胺信号的明显变化
- 批准号:
10222631 - 财政年份:2017
- 资助金额:
$ 1.38万 - 项目类别:
DOPAMINE TRANSPORTER OCCUPANCY BY NOVEL PYROVALERONE ANALOGS, A PET STUDY
新型吡咯戊酮类似物对多巴胺转运蛋白的占用,宠物研究
- 批准号:
8358000 - 财政年份:2011
- 资助金额:
$ 1.38万 - 项目类别:
ADOLESCENT AND ADULT MICE RESPOND DIFFERENTLY TO METHAMPHETAMINE
青少年和成年小鼠对甲基苯丙胺的反应不同
- 批准号:
8357963 - 财政年份:2011
- 资助金额:
$ 1.38万 - 项目类别:
MDMA ELICITS DIFFERENT BEHAVIORS, GENE EXPRESSION IN ADOLESCENT, ADULT MICE
MDMA 在青少年和成年小鼠中引发不同的行为和基因表达
- 批准号:
8357965 - 财政年份:2011
- 资助金额:
$ 1.38万 - 项目类别:
SYNTHESIS, BIOLOGICAL ASSESSMENT OF CANDIDATE MEDICATIONS FOR STIMULANT ABUSE
兴奋剂滥用候选药物的合成和生物学评估
- 批准号:
8358001 - 财政年份:2011
- 资助金额:
$ 1.38万 - 项目类别:
METHAMPHETAMINE MODULATES AXONAL GUIDANCE MOLECULES IN MOUSE HIPPOCAMPUS
甲基苯丙胺调节小鼠海马体中的轴突引导分子
- 批准号:
8172878 - 财政年份:2010
- 资助金额:
$ 1.38万 - 项目类别:
PHENETHYLAMINE (PEA) AND ATTENTION DEFICIT HYPERACTIVITY DISORDER
苯乙胺 (PEA) 和注意力缺陷多动障碍
- 批准号:
8172880 - 财政年份:2010
- 资助金额:
$ 1.38万 - 项目类别:
Methamphetamine and neurodevelopment in adolescent and adult mice
甲基苯丙胺与青少年和成年小鼠的神经发育
- 批准号:
8048397 - 财政年份:2010
- 资助金额:
$ 1.38万 - 项目类别:
相似海外基金
TEST-RETEST RELIABILITY OF 123I-ALTROPANE BINDING POTENTIAL IN MONKEYS
猴子中 123I-阿托烷结合潜力的重测可靠性
- 批准号:
6940200 - 财政年份:2003
- 资助金额:
$ 1.38万 - 项目类别:
ALTROPANE, SPECT OR PET IMAGING PROBE FOR DOPAMINE NEURONS I & IN PRIMATE BRAIN
用于多巴胺神经元的阿托烷、SPECT 或 PET 成像探针 I
- 批准号:
6277798 - 财政年份:1998
- 资助金额:
$ 1.38万 - 项目类别:
RAPID DETECTION OF PARKINSONS DISEASE W/ ALTROPANE
使用阿托烷快速检测帕金森病
- 批准号:
6277801 - 财政年份:1998
- 资助金额:
$ 1.38万 - 项目类别:
ALTROPANE, SPECT OR PET IMAGING PROBE FOR DOPAMINE NEURONS II IN PRIMATE BRAIN
用于灵长类大脑中多巴胺神经元 II 的阿托烷、SPECT 或 PET 成像探针
- 批准号:
6277799 - 财政年份:1998
- 资助金额:
$ 1.38万 - 项目类别:
ALTROPANE, SPECT OR PET IMAGING PROBE FOR DOPAMINE NEURONS III: PARKINSONS BRAIN
用于多巴胺神经元 III 的阿托烷、SPECT 或 PET 成像探针:帕金森病大脑
- 批准号:
6277800 - 财政年份:1998
- 资助金额:
$ 1.38万 - 项目类别:
SPECT LIGAND ALTROPANE DETECTS PARKINSONS DISEASE IN POST MORTEM HUMAN PUTAMEN
SPECT 配体阿托烷可检测死后人类壳核中的帕金森病
- 批准号:
6247687 - 财政年份:1997
- 资助金额:
$ 1.38万 - 项目类别: